Eton Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Eton Pharmaceuticals, Inc. (ETON) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.20% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2019-03-31 was 2.50%.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.70%, a 6.82% increase from fiscal 2024.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.40%, a 6.38% decline from fiscal 2023.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.70%, a 20.51% increase from fiscal 2022.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.90%, a 178.57% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 8 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 8 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | 4.20% 10-Q · filed 2026-08-13 | |||||
| 2025-12-31 | 4.70% 10-K · filed 2026-03-19 | |||||
| 2025-06-30 | 4.70% 10-Q · filed 2026-08-13 | |||||
| 2024-12-31 | 4.40% 10-K · filed 2026-03-19 | |||||
| 2023-12-31 | 4.70% 10-K · filed 2026-03-19 | |||||
| 2022-12-31 | 3.90% 10-K · filed 2025-03-18 | |||||
| 2021-12-31 | 1.40% 10-K · filed 2024-03-14 | |||||
| 2020-12-31 | 0.70% 10-K · filed 2023-03-16 | |||||
| 2019-12-31 | 2.50% 10-K · filed 2022-03-16 | |||||
| 2019-09-30 | 2.50% 10-Q · filed 2019-11-14 | |||||
| 2019-06-30 | 2.50% 10-Q · filed 2019-08-06 | |||||
| 2019-03-31 | 2.50% 10-Q · filed 2019-05-07 | |||||
| 2018-12-31 | 2.90% 10-K · filed 2020-03-05 | |||||
| 2018-09-30 | 2.90% 10-Q · filed 2018-12-20 | |||||
| 2017-12-31 | 2.50% 10-K · filed 2020-03-05 | 2.30% 10-K · filed 2019-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |